Literature DB >> 16522280

The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.

Richard E Pratley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16522280     DOI： 10.1007/s11892-006-0051-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  4 in total

1.  DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Authors:  Nga N Ta; Corinne A Schuyler; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 2.  Minireview: PPARγ as the target of obesogens.

Authors:  Amanda Janesick; Bruce Blumberg
Journal:  J Steroid Biochem Mol Biol       Date:  2011-01-18       Impact factor: 4.292

3.  [Primary prevention of coronary heart disease : Evidence-based drug treatment].

Authors:  Franziska Mühleck; Ulrich Laufs
Journal:  Herz       Date:  2020-02       Impact factor: 1.443

4.  The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice.

Authors:  Weiling Leng; Xinshou Ouyang; Xiaotian Lei; Mingxia Wu; Liu Chen; Qinan Wu; Wuquan Deng; Ziwen Liang
Journal:  Mediators Inflamm       Date:  2016-12-26       Impact factor: 4.711
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.